GlassScriptPhysician profile
Carroll G Odem
NPI 1144224957
$2,323.49
in general payments reported to CMS, 2019-2025
18 companies · $797 in 2025
The $797 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $248 · 2021: $548 · 2022: $155 · 2024: $94.81 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alpha Cognition USA, INC. | $748.14 | 2025 | Zunveyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $748.04 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $346.89 | 2020-2025 | Austedo Xr, Austedo Xr |
| Redhill Biopharma INC. | $92.52 | 2021-2022 | |
| Almatica Pharma LLC | $54.47 | 2021 | |
| Kaleo, INC. | $52.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $51.02 | 2021 | |
| Arbor Pharmaceuticals, INC. | $38.60 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $35.09 | 2021-2024 | Nuedexta |
| Virtus Pharmaceuticals LLC | $28.39 | 2021-2025 | Levorphanol Tartrate |
| Novo Nordisk INC | $21.26 | 2022 | |
| Amgen INC. | $17.43 | 2021 | |
| Pfizer INC. | $16.45 | 2019 | |
| Assertio Therapeutics, INC. | $16.02 | 2019 | |
| Abbvie INC. | $15.01 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $14.89 | 2022 | |
| Biodelivery Sciences International, INC. | $14.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carroll Odem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.